Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center shared on X:
“New preprint from Vividion Therapeutics in collaboration with Julian Downward on targeting the PI3Ka-RAS interaction axis, without the collateral effects on compensatory insulin signaling.
Covalent inhibitors of the RAS binding domain of PI3Ka impair tumor growth driven by RAS and HER2.”
